期刊：Nature Biotechnology
文献作者：Zackery A. Ely; Nicolas Mathey-Andrews; Santiago Naranjo; Samuel I. Gould; Kim L. Mercer; Gregory A. Newby; Christina M. Cabana; William M. Rideout; Grissel Cervantes Jaramillo; Jennifer M. Khirallah; Katie Holland; Peyton B. Randolph; William A. Freed-Pastor; Jessie R. Davis; Zachary Kulstad; Peter M. K. Westcott; Lin Lin; Andrew V. Anzalone; Brendan L. Horton; Nimisha B. Pattada; Sean-Luc Shanahan; Zhongfeng Ye; Stefani Spranger; Qiaobing Xu; Francisco J. Sánchez-Rivera; David R. Liu; Tyler Jacks
出版日期：2024-3-
DOI号：10.1038/s41587-023-01783-y
下载链接：https://www.nature.com/articles/s41587-023-01783-y.pdf
文献链接：https://doi.org/10.1038/s41587-023-01783-y
当前文献来源于 Springer Science and Business Media LLC。
备注信息： |
求助已关闭
10
Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial
